TC BioPharm Ltd
NASDAQ:TCBP
TC BioPharm Ltd
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
